Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2018

Yu Helena A, Suzawa Ken, Jordan Emmet, Zehir Ahmet, Ni Ai, Kim Ryan, Kris Mark G, Hellmann Matthew D, Li Bob T, Somwar Romel, Solit David B, Berger Michael F, Arcila Maria, Riely Gregory J, Ladanyi Marc

Abstract excerpt

Purpose: To identify molecular factors that determine duration of response to EGFR tyrosine kinase inhibitors and to identify novel mechanisms of drug resistance, we molecularly profiled EGFR-mutant tumors prior to treatment and after progression on EGFR TKI using targeted next-generation sequencing.Experimental Design: Targeted next-generation sequencing was performed on 374 consecutive patients with metastatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Genomics

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 29530932
DOI: 10.1158/1078-0432.CCR-17-2961
PMCID: PMC6420806

Genes

EGFR
MTOR
ERBB2
MET
BRAF
CDK4
CTNNB1
FGFR3
FOXA1
KEAP1
MDM2
TTF1
YES1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.PMID 29530932Read ↗

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A ReviewSemantic proximity Read ↗

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.Semantic proximity Read ↗

Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.Semantic proximity Read ↗

Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer.Semantic proximity Read ↗

Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer.Semantic proximity Read ↗

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Concomitant driver mutations in advanced EGFR -mutated non-small-cell lung cancer and their impact on erlotinib treatmentSemantic proximity Read ↗

Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer.Semantic proximity Read ↗

Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.Semantic proximity Read ↗

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.